What top creators are saying about Alnylam Pharmaceuticals, Inc.(ALNY)
A biotechnology company credited as a pioneer in RNA medicines (siRNA).
8 AI-extracted insights from 4 sources — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 6 scored insights about Alnylam Pharmaceuticals, Inc..
The Take
Recent views on Alnylam Pharmaceuticals (ALNY) are mixed but lean slightly bullish: several Shkreli-related comments questioned the selloff and cited profitability and valuation, while acknowledging slower reported growth and pipeline uncertainty. Other mentions merely noted the stock’s steep decline, without offering a company-specific thesis.
Bull Case
- Valuation and profitability: The speaker viewed ALNY as profitable and relatively inexpensive by a rough earnings comparison, questioning the sharp selloff. (The Shkreli Pill, Martin Shkreli)
- Underlying growth: Comments noted rapid underlying growth, despite slower reported revenue growth. (The Shkreli Pill)
- Selloff skepticism: One speaker said they liked the company after its sharp fall, while acknowledging limited review of the earnings. (The Shkreli Pill)
Bear Case
- Growth and pipeline uncertainty: Slower reported growth and uncertainty around pipeline drugs temper the positive valuation view. (The Shkreli Pill, Martin Shkreli)
- Sharp share-price decline: Sources cited ALNY among steep decliners, approximately 60% down, though this was not a fundamental assessment. (The Shkreli Pill, Shkreli Planet)
Catalysts & Targets
- Approximately 60% decline cited in performance and year-to-date screens.
- Earnings were characterized as bad; one speaker said they had not followed them closely.
AI-generated summary. Not investment advice. Learn more.
Top creators covering Alnylam Pharmaceuticals, Inc. (ALNY)
The 4 sources with the most insights about Alnylam Pharmaceuticals, Inc. on Kazuha.
Latest insights about Alnylam Pharmaceuticals, Inc. (ALNY)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Yesterday
Appeared in a performance screen as having fallen about 60%; the screen was not a fundamental review or recommendation.
Wednesday, November 4, 2026
The speaker questioned the sharp selloff, described the company as profitable and relatively inexpensive based on a rough earnings comparison, and noted rapid underlying growth alongside slower reported growth and pipeline uncertainty.
Cited among steep year-to-date decliners at approximately 60% down; the discussion did not provide a company-specific investment thesis.
Tuesday, November 3, 2026
The speaker said they liked the company despite a sharp fall after what they characterized as bad earnings, but acknowledged not having followed the earnings closely.
The speaker viewed the valuation and profitability favorably and questioned the sharp selloff, while acknowledging slowing revenue growth and uncertainty around pipeline drugs.
Thursday, October 15, 2026
Included as a higher-beta biotech example to examine, without a company-specific conclusion.
Tuesday, July 14, 2026
Described as 'super cheap' and categorized as a high-conviction long position.
Monday, February 16, 2026
Credited for its decades of foundational work that led to the success of RNA therapeutics, now considered a 'de-risked modality' and a 'mature platform'.
Yesterday
Appeared in a performance screen as having fallen about 60%; the screen was not a fundamental review or recommendation.
Wednesday, November 4, 2026
The speaker questioned the sharp selloff, described the company as profitable and relatively inexpensive based on a rough earnings comparison, and noted rapid underlying growth alongside slower reported growth and pipeline uncertainty.
Cited among steep year-to-date decliners at approximately 60% down; the discussion did not provide a company-specific investment thesis.
Tuesday, November 3, 2026
The speaker said they liked the company despite a sharp fall after what they characterized as bad earnings, but acknowledged not having followed the earnings closely.
The speaker viewed the valuation and profitability favorably and questioned the sharp selloff, while acknowledging slowing revenue growth and uncertainty around pipeline drugs.
Thursday, October 15, 2026
Included as a higher-beta biotech example to examine, without a company-specific conclusion.
Tuesday, July 14, 2026
Described as 'super cheap' and categorized as a high-conviction long position.
Monday, February 16, 2026
Credited for its decades of foundational work that led to the success of RNA therapeutics, now considered a 'de-risked modality' and a 'mature platform'.
Discussed alongside Alnylam Pharmaceuticals, Inc. (ALNY)
Other assets that creators frequently mention in the same content as Alnylam Pharmaceuticals, Inc..
Frequently asked
Are top creators bullish or bearish on Alnylam Pharmaceuticals, Inc. (ALNY) right now?
Mostly bullish. In the last 30 days, 2 insights were bullish, 1 bearish, and 3 neutral about Alnylam Pharmaceuticals, Inc. (ALNY) across 4 financial sources indexed on Kazuha.
Which podcasters and creators cover Alnylam Pharmaceuticals, Inc. (ALNY) the most?
The most active sources covering Alnylam Pharmaceuticals, Inc. (ALNY) on Kazuha are @realmartinshkreli, @theshkrelipill, @shkreliplanet, Andreessen Horowitz. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Alnylam Pharmaceuticals, Inc. (ALNY) are on Kazuha?
Kazuha has indexed 8 AI-extracted insights about Alnylam Pharmaceuticals, Inc. (ALNY) from 4 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Alnylam Pharmaceuticals, Inc. (ALNY)?
Creators covering Alnylam Pharmaceuticals, Inc. (ALNY) most frequently also discuss MU, SNDK, PLTR, MRNA, AAPL. See the "Discussed alongside" section above for full asset pages.